ReviewPaediatric drugs2018
Treatment Options for Resistant Kawasaki Disease.
Review in Paediatric drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Expression of key genes in IVIG-unresponsive Kawasaki disease and their immune correlation based on bioinformatics analysis.Immunologic research · 2026Article
- Research on gamma globulin unresponsive Kawasaki disease: A review.World journal of clinical pediatrics · 2025Review
- Learning-Based Models for Predicting IVIG Resistance and Coronary Artery Lesions in Kawasaki Disease: A Review of Technical Aspects and Study Features.Paediatric drugs · 2025Review
- IVIG Resistance in Kawasaki Disease: Clinical and Laboratory Risk Factors and the Potential Role of Administration Timing.Journal of inflammation research · 2025Article
- Long-term cardiovascular inflammation and fibrosis in a murine model of vasculitis induced byFrontiers in immunology · 2024Article
- Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome.Physiological research · 2022Review
- Comparison of IVIG resistance predictive models in Kawasaki disease.Pediatric research · 2022Article
- The Associated of the Risk of IVIG Resistance in Kawasaki Disease withJournal of inflammation research · 2022Article
- Association betweenFrontiers in cardiovascular medicine · 2022Article
- Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease.BMC pediatrics · 2021Article
- Prediction of intravenous immunoglobulin resistance in Kawasaki disease in children.World journal of pediatrics : WJP · 2020Article
- Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review.Paediatric drugs · 2020Review
- Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease.Current opinion in pharmacology · 2020Review
- Extracorporeal Membrane Oxygenation Support for Cardiac Dysfunction Due to Kawasaki Disease Shock Syndrome.Frontiers in pediatrics · 2019Article
- A New Scoring System for Prediction of Intravenous Immunoglobulin Resistance of Kawasaki Disease in Infants Under 1-Year Old.Frontiers in pediatrics · 2019Article
- How Should We Classify Kawasaki Disease?Frontiers in immunology · 2018Review
- Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
"Resistant" Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some treatments is considerable. We review the current evidence to guide treatment of resistant Kawasaki disease. Given the relative rarity, there are few trial data, and studies tend to be small and methodologically heterogeneous, making interpretation difficult and limiting generalisability. The literature on resistant Kawasaki disease should be interpreted with reference to current expert consensus guidelines.
Indexed as
Identifiers
29101553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.